Bio-Modeling Systems: The Mechanisms-Based Mecidicine Company
  • 2017: PRESS-RELEASE: Paris-November 16, 2017:BMSystems is selected to pitch at the “Translational Neurosciences Conference” organized by “NeurATRIS” and supported by “eartis” the European Infrastructure For Translational Medicine, comprising more than 80 leading European Institutes.

  • 2017: PRESS-RELEASE: Paris-New-York October 4, 2017: BMSystems, with its 14 independently validated successes to date, is selected by the Galien Foundation for the MedStartUp Award 2017 program first step during the US Galien Prize Forum in New-York.
  • 2017: ANNOUNCEMENT: Latest news:  Press-release from Hospices Civils de Lyon about phage therapy success with Pherecydes Pharma bacteriophages. Pherecydes-Pharma, is BMSystems’ first therapeutic spin-off.
  • 2017: ANNOUNCEMENT: Paris September 7, 2017: The future of Medicine: Bio-Modeling Systems invited to present at the Summer Universities of Fédération Hospitalière de France
  • 2017: ANNOUNCEMENT: Belgium August 26-27, 2017: BMSystems selected to meet Wallonia life Sciences Companies and is invited to the Spa-Francorchamps Formula 1 Race. Great place for top meeting!

  • 2017: ANNOUNCEMENT: Paris July 4, 2017. BMSystems was invited to present at the Conference INSEAD Alumni at BCG Paris Office: Everything you always wanted to know about Digital Health revolution “big promises” but were afraid to ask!

  • 2017: ANNOUNCEMENT: Paris January 17, 2017: BMSytems was invited at the France-India healthcare Summit to present its Computer Augmented Deductive Intelligence platform and its operational successes

  • 2017: ANNOUNCEMENT: Paris January 17, 2017: BMSytems invited to present its collaborative success story with CEA life Sciences at the 10 years anniversary of Medicen Paris Region Health cluster

  • 2017: Happy New Year: Our 8 Resolutions for 2017 to be ready for the upcoming bubble explosion! - Bonne Année: Nos 8 Résolutions pour 2017
  • 2016: INTERVIEW (Post LinkedIn FR avec explications): "Drug Discovery and health Big Data. The enormous Bubble will explode.” (Post LinkedIn ENG with all the explanations)  Manuel GEA, CEO of BMSystems in Biotech & Finances the leading biotech sector information letter

  • 2016: ANNOUNCEMENT: Paris October 5, 2016: BMSystems' CEO invited to present its digital-biology strategy and achievements at the inaugural session of Medicen Paris Region 10th years anniversary

  • 2016: PRESS RELEASE: Paris September 5, 2016: BMSystems selected to present CADI Discovery at the Connexion R&D conference organized by COSMETIC-VALLEY the leading Perfumery & Cosmetic cluster in France.

  • 2016: ANNOUNCEMENT August 1, 2016: BIO-MODELING SYSTEMS' novel Parkinson's therapy mentioned in a Report Covering 179 Companies. A new recognition of CADI Discovery capability to generate novel therapeutic strategies in complex human diseases of which CNS

  • 2016: Updated: Inaugural Presentation Bio-Entrepreneur 2015: The future will be digital and biology, but who will lead? Google? Watson? Alone or MDs, Physiologists, Biologists educating and mastering them combining diagnostics, therapies, connected devices and IT technologies?
Bio-Modeling Systems: The Mechanisms-Based Mecidicine Companys

CADI™ Discovery - description

The Mechanisms-Based Medicine Concept:

Understanding and validating the mechanisms of a disease/disorder becomes the first objective. Finding the most adapted solutions is a necessary consequence of the first objective

  1. DISEASE/DISORDER: Describe the physiopathology of the disease/disorder with clinicians and patients feedback.
  2. MECHANISMS: Discover the causal versus symptomatic mechanisms of the disease/disorder.
  3. BIOMARKERS: Indirectly based on causal mechanisms, identify relevant biomarkers or specific combination, signatures of biomarkers (biological, imagery, physical signals, etc…) that could measure defined mechanistic deregulations at different stages of the disease/disorder.
  4. TARGETS: based on the causal mechanisms, identify what could be the best targets (not only one) to specifically address the causative deregulations.
  5. SOLUTIONS: We harness the mechanisms. Propose the most practical solutions to address the relevant mechanistic deregulations. It is important to notice that the proposed solutions, integrating diagnostics, therapies & patients follow-up, can be combinations of existing drugs, nutriments, devices, e-health, disease prevention tools and services, etc …
  6. FEED BACK LOOP: Integrate the results from e-R&D or e-Health experimentations into the validation process to improve global patient and disease/disorder follow-up.

The Life science modeling dilemma

  • The mechanisms of life are complex, non-linear and integrative.
  • In “living complex” systems, the functions of biological components and mechanisms are event and context-dependent. Classical “Cartesian” modeling concepts & approaches, valid for the majority of man-made artifacts, imply the concept of a “blue-print”. But this concept is at the opposite of biological reality.
  • While “Cartesian” Bioinformatics and Mathematical tools have proven to be efficient to collect, structure, analyze, simulate specific functions to test or generate innovative hypotheses, yet…
  • The “garbage in, garbage out” reality, tells us that the information produced and published (even in leading scientific journals) is necessarily ALWAYS incomplete, biased and erroneous to unknown extents.
  • Big Data, due to life sciences reality, generally means “Big Garbage”.
  • High value Smart Data, necessarily needs to be contextualized, with patients base-lines, and related to biological mechanisms.
  • Statistics, serendipity or massive big data cannot be the “only” medical research options to deciphering the mechanisms of complex diseases.
  • Despite increasing investments in Technology & I.T., major drugs products submissions to FDA are constantly declining.

CADI™ Discovery platform a proven operational answer, to implement Mechanisms-Based Medicine,

  • A heuristic multi-systems multi-scale systems biology approach to addresses complex, non-linear and integrative issues.
  • A revised discovery and validation process to address complex diseases issues using necessary mechanisms understanding.
  • A novel continuum between e-R&D and e-Health to enlarge and strengthen the translational medicine paradigm and extract the maximum pertinent value from scientific, medical & health data.
  • A proactive search of cost-effective solutions with lower short term failure risks exploiting the growing number of well documented off-patent molecules, multiple devices and e-health tools, disease prevention tools and services.
  • The discovery of new drugs is possible.
  • A systematic search of synergies between our research domains to optimize our proprietary CADI™ Knowledge database value through cost-effective novel applications


CADI™ Modeling : The first “heuristic” modeling approach, successfully applying its 5 principles

  1. “Architectural Principles” Approach;
  2. “Negative Selection” Process;
  3. “4 steps validation” Process;
  4. Broad life sciences & IT Expertise;
  5. “Synergic collaboration” with classical IT partners.

The second generation tools,  CADI™ Process, development started in 2002

The unique CADI™ 4 steps validation process

The CADI™ 4 steps validation process starts when the integrative biology researchers generate the initial CADI™ model

The initial CADI™ Ver.0 model is constructed by "integrative biology" researchers.

  • Step 1: For each loop, "integrative biology" researchers integrate the experimental results to generate the next CADI™ Ver. n+1 model .
  • Step 2: CADI™ model forecasts are defined by both experimental and integrative biology researchers The "experimental biology" researchers define and/or invent new innovative experimentations to test the models forecasts.
  • Step 3: "Experimental biology" researchers implement the innovative experimental approaches to test the model forecasts.
  • Step 4: Experimental results are analyzed and interpreted by both experimental and integrative biology researchers.

The CADI™ 4 steps validation process stops when no key unexpected results are reported.

The first generation (abandoned in 2001): Bio-Graph™ (1998-2001)

  • This initial "Cartesian" integrative plate-form, called "Bio-Graph™" because largely based upon graph theories, was developed over the period 1998-2001
  • This technology allowed the production of the first biological models of complex human pathologies ever produced (Tamoxifen resistance, partly with the CADI™ prototype)
  • However, this approach was extremely limited on several fronts:
    • It required that all the papers be annotated  before use, etc...
    • It required massive amounts of human intervention at all stages of the analytical process and,
    • while allowing to efficiently analyze at the cellular level, it was woefully inadequate for tasks where different tissues or organs had to be taken into consideration.
*CADI™: Computer Assisted Deductive Integration

Bio-Modeling Systems: a leading Integrative Heuristic Systems Biology / Predictive Integrative Biology Mechanisms-Based Medicine company that delivers